{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T13:10:01Z","timestamp":1750165801450,"version":"3.41.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jdcr.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:40:21Z","timestamp":1743655221000},"page":"115-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Talimogene laherparepvec induced bullous pemphigoid"],"prefix":"10.1016","volume":"60","author":[{"given":"Sahar","family":"Davoudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fade","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2685-4584","authenticated-orcid":false,"given":"Jordan","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jdcr.2025.03.016_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.03.016_bib2","first-page":"265","article-title":"The safety of talimogene laherparepvec for the treatment of advanced melanoma","volume":"16","author":"Gangi","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.jdcr.2025.03.016_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.03.016_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2023.02.017","article-title":"Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: a multi-hospital cohort study","volume":"88","author":"Leung","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2025.03.016_bib5","series-title":"Janeway's immunobiology","first-page":"399","article-title":"The humoral immune response","author":"Murphy","year":"2017"},{"issue":"1","key":"10.1016\/j.jdcr.2025.03.016_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12887-017-0813-0","article-title":"Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger","volume":"17","author":"Baroero","year":"2017","journal-title":"BMC Pediatr"},{"issue":"6","key":"10.1016\/j.jdcr.2025.03.016_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jdcr.2025.03.016_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdcr.2025.03.016_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953546","article-title":"Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid-A retrospective, monocentric study","volume":"13","author":"Schauer","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.03.016_bib10","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625001353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:28:51Z","timestamp":1750163331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625001353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"alternative-id":["S2352512625001353"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.016","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Talimogene laherparepvec induced bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}